Eovist Gadoxetate Sodium Enhanced Magnetic Resonance Imaging (Mri) As A Biomarker For Aggressive Prostate Cancer
Posted Date: Jun 10, 2019
- Investigator: Sadhna Verma
- Specialties: Cancer, Oncology, Prostate Cancer
- Type of Study: Device
To determine if Gadoxetate Sodium has the same ability as gadolinium to identify prostate cancer by comparing enhancement ratios and to test if the diagnosis from Gadoxetate Sodium imaging can identify more aggressive prostate cancer that are likely to occur.
To Be Eligible You Must Be At Least 18 Years Of Age, Have Clinically Localized Prostate Cancer, And Normal Liver Function. No Prostatectomy, Chronic Kidney Disease Or Pacemakers.
For More Information:
Uc Cancer Institute